Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Checkpoint Inhibition After Autologous HSCT in High-Risk Recurrent Disease
NCT02681302Phase 2Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Jun 2016
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in multiple myeloma (MM), lymphoma, sponsored by Hackensack Meridian Health. Started Jun 2016; status: terminated.
02
Drugs
ipilimumabnivolumab
03
Conditions
multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on NCT02681302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681302.